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Abstract Various bio-active substances in amphibian skins play important roles in survival of the amphibians. Many protease
inhibitor peptides have been identified from amphibian skins, which are supposed to negativelymodulate the activity of proteases to
avoid premature degradation or release of skin peptides, or to inhibit extracellular proteases produced by invading bacteria.However,
there is no information on the proteinase inhibitors from the frog Lepidobatrachus laeviswhich is unique in South America. In this
work, a cDNA encoding a novel trypsin inhibitor-like (TIL) cysteine-rich peptide was identified from the skin cDNA library of L.
laevis. The 240-bp coding region encodes an 80-amino acid residue precursor protein containing 10 half-cysteines. By sequence
comparison and signal peptide prediction, the precursor was predicted to release a 55-amino acid mature peptide with amino acid
sequence, IRCPKDKIYKFCGSPCPPSCKDLTPNCIAVCKKGCFCRDGTVDNNHGKCVKKENC. The mature peptide was
named LL-TIL. LL-TIL shares significant domain similarity with the peptides from the TIL supper family. Antimicrobial and
trypsin-inhibitory abilities of recombinant LL-TILwere tested. Recombinant LL-TIL showed no antimicrobial activity, while it had
trypsin-inhibiting activitywith aKiof 16.5178 lM.These results suggested therewasTILpeptidewith proteinase-inhibiting activity
in the skin of frog L. laevis. To the best of our knowledge, this is the first report of TIL peptide from frog skin.
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1 Introduction
Amphibian skin has great molecular diversity and is a
versatile organ important for everyday survival. Amphibian
skin secretions are a subject of interest because of the
skin’s unique chemical properties and biosynthesis path-
ways and because of its potential clinical applications [1].
Over the past several decades, bioactive components of
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amphibian skin secretions, especially biologically active
peptides, have been extensively studied [2–6]. More than
100 families of peptides including about 2000 from
amphibian skin have been described [1].
Many protease inhibitor peptides smaller than 10 kDa
have been identified from amphibian skins [7–11]. These
include bi-functional peptides with both protease-inhibitory
and antimicrobial functions. Protease inhibitor peptides are
categorized broadly based on structural motifs or the pro-
tease inhibited. Using the presence of a defined structural
motif, these peptides can be classified into Kunitz, Kasal,
and Bowman-Birk classes; by inhibited protease, they are
classified into cystatins, serpins, and tissue inhibitors of
metalloproteases [10, 12]. However, there are rare reports
of trypsin inhibitor-like cysteine rich (TIL) peptides from
amphibian skin.
TIL domain typically contains ten cysteine residues that
form five disulfide bridges. The cysteine residues that form
the disulfide bridges are C1–C7, C2–C6, C3–C5, C4–C10
and C8–C9 [13]. Besides the trypsin inhibitors, it is inter-
esting that many extracellular proteins also contain multi-
ple TIL domains. Peptides containing the TIL domain
generally consist of 56–84 amino acid residues. It was
shown that a typical peptide of the TIL family is able to
inhibit proteinase, and thus play roles in biological pro-
cesses, such as inhibition of anticoagulation and partici-
pation in immune response [14–17]. Because TIL domain-
containing peptides exhibit some unique features, such as
compact rigidity, well-defined structure and small size,
they are used as a molecular scaffold for the development
of new pharmaceutical drugs [18].
However, only a small number of the peptides con-
taining TIL domain have been identified so far, which
hinders the structure–function relationship investigation,
evolutionary analysis and potential uses of this kind of
peptides [18]. In this work we identified a TIL peptide from
the skin of from the frog L. laevis and conformed its pro-
teinase-inhibiting activity.
2 Results and Discussion
2.1 Cloning of LL-TIL Precursor
As illustrated in Fig. 1a, a cDNA encoding an 80-amino
acid residue (aa) precursor protein was cloned from the
skin cDNA library of the frog L. laevis. The precursor
includes a predicted signal peptide and mature peptide
(named LL-TIL). Mature LL-TIL is composed of 55 aa
including 10 half-cysteines. MW/pI tool (http://www.
expasy.ch/tools/pi_tool.html) showed that it had a
predicted molecular mass of 6164.29 and an isoelectric
point (pI) of 8.88.
BLAST search revealed that the sequence of LL-TIL
showed significant domain similarity to arthropod peptides
from the TIL supper family including SjAPI (Q8T0W5),
Apim6 (NP_001035360), Ixodidin (P83516), AcCI
(AGB06350) and BmSI-7 (ACV83329) as illustrated in
Fig. 1b. SjAPI and Apim6 are produced and secreted by the
venom glands of the scorpion or bee venom [14, 16, 19].
SjAPI potently inhibits the activities of a-chymotrypsin
and elastase [14]. Api m6 is a bee venom allergen that
binds to IgE [16]. Ixodidin is from hemocytes of the cattle
tick [15]. It is able to inhibit the activities of chymotrypsin
and elastase. It also possesses weak antimicrobial activities
and is involved in immune response. AcCI is from the
honeybee [20]. It inhibits the activities of chymotrypsin
and elastase. BmSI-7 (ACV83329) is expressed in the eggs,
ovary, gut, salivary gland and hemocytes of tick [17].
BmSI-7 inhibits the activity of subtilisin, and might par-
ticipate in defense and inflammatory response. Although
the primary structures of these peptides vary, they share a
common cysteine motif: CX8–9CX3–5CX3–4C
X6–10CX3–6 CX3–5 CX1CX11–13CX5C (X stands for
any amino acid residue). There is a protease-binding loop
located between C5 and C6 in the TIL peptides (Fig. 1b).
The three residues are the active site residues that affect the
activities and specificities of the peptides [13–17].
According to the residues at the proteinase-binding loop,
LL-TIL was predicted to have trypsin- or chymotrypsin-
inhibiting activity. In order to verify the biological activity
of LL-TIL, it was expressed as a recombinant peptide.
2.2 Expression and Purification of
Recombinant LL-TIL
The expression of recombinant LL-TIL was induced by
IPTG (Fig. 2a). The fusion protein (Fig. 2a) isolated from
the His-binding resin Ni2? affinity column was cut by
50 % formic acid (50 C, 24 h) (Fig. 2b). The mature LL-
TIL was released from the fusion protein, and then purified
by Sephadex G-50 size-exclusion chromatography
(Fig. 2c), C4 and C8 RP-HPLC (Fig. 2d, e) columns.
MALDI-TOF mass spectrometry analysis gave a mass of
6160.03 (Fig. 2f) that is accord with the predicted molec-
ular weight. The homogeneity of the purified recombinant
LL-TIL was confirmed by SDS-PAGE and mass spec-
trometry analysis (Fig. 2e, f). The first 15 amino acids of
the N-terminal sequence of IL-TIL was further confirmed
by Edman degradation sequencing to be the same as the
sequence deduced from its cDNA.
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2.3 Antimicrobial Activities
Recombinant LL-TIL showed no antimicrobial abilities
against the tested microorganisms including Gram positive
bacterium Staphylococcus aureus (ATCC 25923), Gram-
negative bacteria Escherichia coli (ATCC 25922), Bacillus
subtilis (ATCC 6633) and fungus Candida albicans
(ATCC 20032) (Data not shown).
2.4 Proteinase-Inhibiting Activity
LL-TIL did not inhibit the hydrolysis of synthetic chro-
mogenic substrates by thrombin, chymotrypsin, elastase,
plasmin and substilisin (Data not shown). However, it
inhibited the activity of trypsin. The reaction velocity of
trypsin with chromogenic substrate in the presence of LL-
TIL was shown in Table 1. By Dixon plot (Fig. 3), the Ki
was calculated to be 16.5178 lM. Compared with Bow-
man - Birk-like trypsin inhibitors from frog [8], the
activity of LL-TIL is lower than Ranacyclin B3, -B5, and
-B-RL1 which had trypsin-inhibitory abilities with a Ki
order of 10-8 M. Its activity is similar to Ranacyclin-B-
RN1, -B-RN2, -B-RN6, -B-LK1, and -B-LK2 which had a
Ki order of 10-6 M. However, its activity is much high
than Ranacyclin-B-AL1 which had weak trypsin-in-
hibitory activity with a Ki of 10-4 M. Besides, its activity
is lower than the Kunitz inhibitors from European frog
Bombina bombina, which had Ki values in the range of
0.1–1 lM [21]. Presently, the biological role of proteinase
inhibitory peptides in amphibian skins is explained mainly
by two hypotheses. One is that several enzymes are
involved in peptide precursor processing or peptide
degradation in the skin and proteinase inhibitors nega-
tively modulate the activity of these proteases to avoid
premature degradation or release of skin peptides [22].
The other hypothesis is that the peptides are surface anti-
infective agent similar to AMPs because they inhibit
extracellular proteases produced by invading bacteria
[21]. LL-TIL showed trypsin-inhibiting activity, but its
biological target and function are not known. Further
work is needed to address this issue.
3 Experimental Section
3.1 cDNA Library Construction
One adult male frog of L. laevis was purchased from pet
market in Nanjing, Jiangsu Province of China. All appli-
cable institutional and/or national guidelines for the care
and use of animals were followed. Total RNA was
extracted from the skin of the frog by TRIzol reagent (Life
Technologies, Ltd.). The cDNA was synthesized using a
SMARTTM PCR cDNA synthesis kit purchased from
Clontech (Palo Alto, CA). The primers used in the first
strand synthesis were cDNA 30 SMART CDS Primer II A,
50-AAGCAGTGGTATCAACGCAGAGTACT (30) VN-30
(N = A, C, G or T; V = A, G or C), and SMART II A
oligonucleotide, 50-A AGCAGTGGTATCAACGCAGAG
TACGCGGG-30. The second strand was amplified using
Advantage polymerase by 50 PCR primer II A, 50-A AGCA
GTGGTATCAACGCAGAGT-30. A directional cDNA
library was constructed with a plasmid cloning kit (Su-
perScriptTM Plasmid System, GIBCO/BRL) following the
Fig. 1 The nucleotide sequence encoding LL-TIL precursor (a) and
the precursor sequence alignment of LL-TIL with SjAPI (Q8T0W5),
Apim6 (NP_001035360), Ixodidin (P83516), AcCI (AGB06350) and
BmSI-7 (ACV83329) (b). The signal peptide is italic. The sequence
of mature peptide is boxed. The asterisk (*) indicates the stop codon.
The polyA signal (AATAAA) is underlined. The conserved cysteine
motifs are highlighted in grey. The bar (-) was introduced for optimal
comparison
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instructions of manufacturer, producing a library of about
1.0 9 106 independent colonies.
3.2 cDNA Cloning and Construction of Recombinant
Vector
More than one thousand clones were randomly selected
and isolated. They are subjected to DNA sequencing by an
applied biosystems DNA sequencer (ABI 3730). A clone
was found to encode a precursor containing mature peptide
(named LL-TIL) which shares a significant sequence sim-
ilarity with the peptides from TIL supper family. E. coli
Rosetta-gami (DE3) and plasmid pET-32a (?) were used
to express the recombinant LL-TIL. A formic acid cleav-
age site, -(GACCCG)-, was designed at the right upstream
to the LL-TIL coding sequence. Rare codons for Asp and
Pro were replaced by more frequently used ones based on
E. coli codon usage. Two forward primers: LL-50-1 (50-GA
TGATGACCCGATTCGCTGTC-30), LL-50-2 (50-CGGGG
TACCGATGATGATGAC-30) and a reverse primer LL-30
(50-CCCAAGCTTGAGGTGGCGG-30) were designed.
LL-50-1 contains the formic acid cleavage site. LL-50-2
and LL-30 contains recognition site for Kpn I and Hind
III, respectively. The PCR conditions were 4 min at
temperature of 95 C, and then running 26 cycles with a
temperature profile of 30 s at 94 C, 40 s at 60.5 C, and
50 s at 72 C, at last holding at 72 C for 10 min. The
final purified PCR product was digested with Kpn I and
Hind III, and ligated into the pET-32a (?) plasmid with
T4 DNA ligase at the corresponding restriction sites. The
Fig. 2 Expression and purification of LL-TIF fusion protein in E. coli
Rosetta-gami (DE3). a Expression of LL-TIL fusion protein in E. coli
Rosetta-gami (DE3) and analyzed by SDS-PAGE (12 %). M, protein
molecular weight marker; lane 1, LL/pET-32a (?) uninduced; lane 2,
LL/pET-32a (?) induced supernatant. The target molecular weight is
indicated by an arrow. b SDS-PAGE (15 %) analysis of eluted LL-
TIL fusion protein from His-binding resin Ni2? affinity column (lane
2) and its digested products by formic acid (lane 1). The fusion
protein and the released LL-TIF are indicated by arrows (up for the
fusion protein and low for the released LL-TIF, respectively).
c Sephadex G-50 chromatography of digested products of LL-TIF
fusion protein equilibrated with 0.1 M Na2HPO4–NaH2PO4. The
elution was performed at a flow rate of 0.3 mL/min with the same
buffer. d The protein peak III (indicated by an arrow) containing
trypsin-inhibiting activity was further purified on a Hypersil C4 RP-
HPLC column equilibrated with 0.1 % (v/v) trifluoroacetic acid in
water. The elution was performed with the gradients of acetonitrile in
0.1 % (v/v) trifluoroacetic acid in water at a flow rate of 0.7 mL/min.
Fractions containing trypsin-inhibiting activity is indicated by an
arrow. e The recombinant LL-TIF was further purified on the
Spherisob C8 RP-HPLC column. Fractions containing trypsin-inhibit-
ing activity is indicated by an arrow. f Mass spectrum analysis of
purified recombinant LL-TIF on a MALDI-TOF mass spectrometer.
Inserts in e indicate SDS-PAGE (15 %) of purified LL-TIF
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resultant recombinant vector was referred to as LL/pET-
32a (?).
3.3 Expression of Recombinant LL-TIL
The LL/pET-32a (?) construct was transformed into the
E. coli strain Rosetta-gami (DE3) for protein expression.
After overnight growth in 1 mL LB media (with 100 lg/
mL ampicillin and 12.5 lg/mL tetracycline) at 37 C, this
bacterial culture was used to inoculate another 1000 mL
LB media. When the absorbance at 600 nm was reached
0.6, isopropyl b-D-1-Thiogalactopyranoside (IPTG) (final
concentration of 0.8 mM) was added to initiate fusion
protein expression by culturing at 28 C. Following addi-
tional 3 h cultivation, cells were harvested by centrifuga-
tion at 100009g for 15 min. The histidine-tagged carrier
and residual undigested fusion protein were released from
the cell by sonication, and applied on a His-binding resin
Ni2? affinity column (Merck). The LL-TIL-containing
fusion protein was hydrolyzed by formic acid (50 %) at
50 C for 24 h according to the manufacturer’s instruc-
tions. The reaction mixture was then lyophilized.
3.4 Purification of Recombinant LL-TIL
Lyophilized sample containing recombinant LL-TIL
(200 mg) was dissolved in 2 mL of 0.1 M Na2HPO4–
NaH2PO4, pH 6.0. And then applied to a Sephadex G-50
size-exclusion chromatography column (1000 9 26 mm)
equilibrated with 0.1 M Na2HPO4–NaH2PO4, pH 6.0. The
elution was performed at a flow rate of 0.3 mL/min with
the same buffer. The absorbance of the eluate was moni-
tored at 280 nm. Every eluted fraction (3 mL) was col-
lected and subjected to antimicrobial and trypsin inhibitory
assays as described below. Fractions containing trypsin-
inhibiting activity were pooled, lyophilized, and re-sus-
pended in 5 mL 0.1 M Na2HPO4–NaH2PO4, pH 6.0 for
purification by a C8 reverse phase high-performance liquid
chromatography (RP-HPLC, Hypersil C4, 25 9 0.46 cm)
column. The LL-TIL containing fraction was lyophilized
and further purified with the Spherisob C8 column on
HPLC. The purity of the peptide was determined by SDS–
polyacrylamide gel electrophoresis (SDS-PAGE) and mass
spectrometry analysis.
3.5 SDS-PAGE and Protein Concentration
Determination
SDS-PAGE was performed under reduced and/or non-re-
duced conditions. Protein samples were loaded onto 12 or
15 % polyacrylamide gels. Protein bands were visualized
after using a standard Comassie blue stain. The protein
concentration was determined by a protein assay kit (Bio-
Rad, Hercules, CA) using bovine serum albumin (BSA) as
a standard.
3.6 Mass Spectrometry
Mass spectrometry analysis was performed on a matrix-
assisted laser desorption ionization time-of-flight mass
spectrometer (MALDI-TOF–MS) AXIMA CFR (Kratos
Analytical). a-Cyano-4-hydroxycinnamic acid (CHCA)
was used as matrix. The specific parameters were as fol-
lows: the ion acceleration voltage was 20 kV, the accu-
mulating time of single scanning was 50 s, polypeptide
mass standard (Kratos Analytical) serving as external
standard.
3.7 Serine Protease Inhibitory Testing
Effects of the tested samples on the hydrolysis of synthetic
chromogenic substrates by different serine proteases were
assayed in 0.05 M Tris–HCl, pH 7.8 (for trypsin, Sigma
T4665; thrombin, Sigma T4393; chymotrypsin, Sigma
C4129; elastase, Sigma E1250; plasmin, Sigma P1867) or
pH 8.45 (for substilisin, Sigma P5380) buffer at 37 C. The
Table 1 Reaction velocities of trypsin with substrate at different
concentrations in the presence of LL-TIL (I)
[I] lM [S] = 0.2 mM [S] = 0.4 mM
Vav 1/Vav Vav 1/Vav
0 0.2641 3.7864 0.3656 2.7352
12.987 0.1893 5.2826 0.2584 3.8700
25.974 0.1368 7.3116 0.2063 4.8481
The values are means of three duplicate experiments
Fig. 3 The Ki of LL-TIF on trypsin is 16.5178 lM by Dixon plot
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protease (trypsin, 10 nM; thrombin, 10 nM; chymotrypsin,
21 nM; elastase, 23 nM and substilisin, 30 nM) and dif-
ferent amounts of LL-TIL (final concentrations ranging
from 0.0 to 20 lM) were pre-incubated for 10 min at
37 C. The reaction was initiated by the addition of the
substrate B-3133 (N-benzyl-L-arginine-4-nitroanilide-hy-
drochride-pNA, Sigma) (0.5 mM). The formation of p-ni-
troaniline was monitored continuously at 405 for 2 min.
For chymotrypsin, the reaction was monitored at 253 nm.
The inhibition constant Ki was determined according to the
reported method [23].
3.8 Antimicrobial Assays
For antimicrobial assays, several microorganisms including
Gram positive bacterium S. aureus (ATCC 25923), Gram-
negative bacteria E. coli (ATCC 25922), B. subtilis (ATCC
6633), and fungus C. albicans (ATCC 20032) were
obtained from Kunming Medical College. They were first
grown in LB (Luria–Bertani) broth or yeast extract–pep-
tone–dextrose broth as our previous methods [24]. MIC
(minimal inhibitory concentration) of tested sample against
these microorganisms was determined as previous reports
[24]. The MIC is defined as the lowest concentration of
tested sample to inhibit microorganism growth.
4 Conclusion
This work identified and characterized a novel trypsin
inhibitor-like cysteine-rich (TIL) peptide in the frog of L.
laevis. Its biological activities were investigated. LL-TIL
showed potential proteinase inhibiting activity with no
antimicrobial activity. Though its biological target and
function are elusive, it may negatively modulate the
activity of proteases to avoid premature degradation or
release of skin peptides, or inhibit extracellular proteases
produced by invading bacteria. This is the first report of
TIL peptide with proteinase inhibiting activity in frog. LL-
TIL may be useful in the studies of the structure–function
relationship, evolutionary analysis and potential uses of
TIL peptides.
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